tiprankstipranks
C4 Therapeutics (CCCC)
NASDAQ:CCCC
US Market

C4 Therapeutics Income Statement

85 Followers

C4 Therapeutics Income Statement

Last quarter (Q2 2022), C4 Therapeutics's total revenue was $13.83M, an increase of 41.44% from the same quarter last year. In Q2, C4 Therapeutics's net income was $-27.41M. See C4 Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ 50.07M$ 45.78M$ 33.20M$ 21.38M$ 19.36M
Cost of Revenue
-----
Gross Profit
-----
Operating Expense
$ 148.33M$ 127.92M$ 93.64M$ 56.83M$ 35.75M
Operating Income
$ -98.26M$ -82.13M$ -60.45M$ -35.45M$ -16.39M
Net Non Operating Interest Income Expense
$ -1.11M$ -1.76M$ -836.00K$ 2.16M$ 685.00K
Other Income Expense
--$ -5.68M$ 325.00K$ -7.00K
Pretax Income
$ -99.37M$ -83.89M$ -66.96M$ -33.30M$ -15.71M
Tax Provision
-$ 0.00$ -626.00K$ 804.00K$ 0.00
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
$ -99.37M$ -83.89M$ -66.33M$ -34.10M$ -24.11M
Basic EPS
$ -2.03$ -1.82$ -5.83$ -2.31$ -1.63
Diluted EPS
$ -2.03$ -1.82$ -5.83$ -2.31$ -1.63
Basic Average Shares
$ 194.73M$ 46.04M$ 11.37M$ 14.79M$ 14.79M
Diluted Average Shares
$ 194.73M$ 46.04M$ 11.37M$ 14.79M$ 14.79M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
$ 148.33M$ 127.92M$ 93.64M$ 56.83M$ 35.75M
Net Income From Continuing And Discontinued Operation
$ -99.37M$ -83.89M$ -66.33M$ -34.10M$ -15.71M
Normalized Income
$ -99.37M$ -83.89M$ -60.71M$ -34.10M$ -15.71M
Interest Expense
$ 2.14M$ 2.15M$ 1.23M$ 0.00-
EBIT
$ -97.23M$ -81.75M$ -65.73M$ -33.30M$ -16.39M
EBITDA
$ -95.84M$ -80.25M$ -64.11M$ -31.70M$ -15.12M
Currency in USD

C4 Therapeutics Earnings and Revenue History


What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis